473 related articles for article (PubMed ID: 38473975)
1. The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention.
Tolar M; Hey JA; Power A; Abushakra S
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473975
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
3. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
4. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
Tolar M; Hey J; Power A; Abushakra S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198582
[TBL] [Abstract][Full Text] [Related]
5. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease.
Ono K; Tsuji M
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023927
[TBL] [Abstract][Full Text] [Related]
6. Brain amyloid-β oligomers in ageing and Alzheimer's disease.
Lesné SE; Sherman MA; Grant M; Kuskowski M; Schneider JA; Bennett DA; Ashe KH
Brain; 2013 May; 136(Pt 5):1383-98. PubMed ID: 23576130
[TBL] [Abstract][Full Text] [Related]
7. Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease.
Brody DL; Jiang H; Wildburger N; Esparza TJ
Alzheimers Res Ther; 2017 Aug; 9(1):62. PubMed ID: 28818091
[TBL] [Abstract][Full Text] [Related]
8. Resting microglia react to Aβ42 fibrils but do not detect oligomers or oligomer-induced neuronal damage.
Ferrera D; Mazzaro N; Canale C; Gasparini L
Neurobiol Aging; 2014 Nov; 35(11):2444-2457. PubMed ID: 24973120
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
Behl T; Kaur I; Fratila O; Brata R; Bungau S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
[TBL] [Abstract][Full Text] [Related]
10. Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease.
Thal DR; Walter J; Saido TC; Fändrich M
Acta Neuropathol; 2015 Feb; 129(2):167-82. PubMed ID: 25534025
[TBL] [Abstract][Full Text] [Related]
11. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.
Viola KL; Klein WL
Acta Neuropathol; 2015 Feb; 129(2):183-206. PubMed ID: 25604547
[TBL] [Abstract][Full Text] [Related]
12. Advances in fluorescent probes for detection and imaging of amyloid-β peptides in Alzheimer's disease.
Zhang Y; Ding C; Li C; Wang X
Adv Clin Chem; 2021; 103():135-190. PubMed ID: 34229849
[TBL] [Abstract][Full Text] [Related]
13. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease as oligomeropathy.
Ono K
Neurochem Int; 2018 Oct; 119():57-70. PubMed ID: 28821400
[TBL] [Abstract][Full Text] [Related]
15. How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters.
Matsuzaki K
Acc Chem Res; 2014 Aug; 47(8):2397-404. PubMed ID: 25029558
[TBL] [Abstract][Full Text] [Related]
16. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
[TBL] [Abstract][Full Text] [Related]
17. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
18. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.
de la Monte SM
Drugs; 2012 Jan; 72(1):49-66. PubMed ID: 22191795
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of cellular prion protein within β-amyloid oligomer plaques in aged human brains.
Takahashi RH; Yokotsuka M; Tobiume M; Sato Y; Hasegawa H; Nagao T; Gouras GK
Brain Pathol; 2021 Sep; 31(5):e12941. PubMed ID: 33624334
[TBL] [Abstract][Full Text] [Related]
20. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
Imbimbo BP; Ippati S; Watling M; Imbimbo C
Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
